TY - JOUR
T1 - A global action agenda for turning the tide on fatty liver disease
AU - Lazarus, Jeffrey V.
AU - Mark, Henry E.
AU - Allen, Alina M.
AU - Arab, Juan Pablo
AU - Carrieri, Patrizia
AU - Noureddin, Mazen
AU - Alazawi, William
AU - Alkhouri, Naim
AU - Alqahtani, Saleh A.
AU - Anstee, Quentin M.
AU - Arrese, Marco
AU - Bataller, Ramon
AU - Berg, Thomas
AU - Brennan, Paul N.
AU - Burra, Patrizia
AU - Castro-Narro, Graciela E.
AU - Cortez-Pinto, Helena
AU - Cusi, Kenneth
AU - Dedes, Nikos
AU - Duseja, Ajay
AU - Francque, Sven M.
AU - Gastaldelli, Amalia
AU - Hagström, Hannes
AU - Huang, Terry T.-K.
AU - Ivancovsky Wajcman, Dana
AU - Kautz, Achim
AU - Kopka, Christopher J.
AU - Krag, Aleksander
AU - Newsome, Philip N.
AU - Rinella, Mary E.
AU - Romero, Diana
AU - Sarin, Shiv Kumar
AU - Silva, Marcelo
AU - Spearman, C. Wendy
AU - Terrault, Norah A.
AU - Tsochatzis, Emmanuel A.
AU - Valenti, Luca
AU - Villota-Rivas, Marcela
AU - Zelber-Sagi, Shira
AU - Schattenberg, Jörn M.
AU - Wong, Vincent Wai-Sun
AU - Younossi, Zobair M.
N1 - Funding Information:
The data collection and analysis were funded by the European Association for the Study of the Liver (EASL), with support from Takeda, MSD, Bristol-Myers-Squibb Company, and Apollo Endo.
Copyright:
© 2023 The Author(s). Published by Wolters Kluwer Health, Inc.
PY - 2024/2
Y1 - 2024/2
N2 - Background and Aims: Fatty liver disease is a major public health threat due to its very high prevalence and related morbidity and mortality. Focused and dedicated interventions are urgently needed to target disease prevention, treatment, and care. Approach and Results: We developed an aligned, prioritized action agenda for the global fatty liver disease community of practice. Following a Delphi methodology over 2 rounds, a large panel (R1 n = 344, R2 n = 288) reviewed the action priorities using Qualtrics XM, indicating agreement using a 4-point Likert-scale and providing written feedback. Priorities were revised between rounds, and in R2, panelists also ranked the priorities within 6 domains: epidemiology, treatment and care, models of care, education and awareness, patient and community perspectives, and leadership and public health policy. The consensus fatty liver disease action agenda encompasses 29 priorities. In R2, the mean percentage of “agree” responses was 82.4%, with all individual priorities having at least a super-majority of agreement (> 66.7% “agree”). The highest-ranked action priorities included collaboration between liver specialists and primary care doctors on early diagnosis, action to address the needs of people living with multiple morbidities, and the incorporation of fatty liver disease into relevant non-communicable disease strategies and guidance. Conclusions: This consensus-driven multidisciplinary fatty liver disease action agenda developed by care providers, clinical researchers, and public health and policy experts provides a path to reduce fatty liver disease prevalence and improve health outcomes. To implement this agenda, concerted efforts will be needed at the global, regional, and national levels.
AB - Background and Aims: Fatty liver disease is a major public health threat due to its very high prevalence and related morbidity and mortality. Focused and dedicated interventions are urgently needed to target disease prevention, treatment, and care. Approach and Results: We developed an aligned, prioritized action agenda for the global fatty liver disease community of practice. Following a Delphi methodology over 2 rounds, a large panel (R1 n = 344, R2 n = 288) reviewed the action priorities using Qualtrics XM, indicating agreement using a 4-point Likert-scale and providing written feedback. Priorities were revised between rounds, and in R2, panelists also ranked the priorities within 6 domains: epidemiology, treatment and care, models of care, education and awareness, patient and community perspectives, and leadership and public health policy. The consensus fatty liver disease action agenda encompasses 29 priorities. In R2, the mean percentage of “agree” responses was 82.4%, with all individual priorities having at least a super-majority of agreement (> 66.7% “agree”). The highest-ranked action priorities included collaboration between liver specialists and primary care doctors on early diagnosis, action to address the needs of people living with multiple morbidities, and the incorporation of fatty liver disease into relevant non-communicable disease strategies and guidance. Conclusions: This consensus-driven multidisciplinary fatty liver disease action agenda developed by care providers, clinical researchers, and public health and policy experts provides a path to reduce fatty liver disease prevalence and improve health outcomes. To implement this agenda, concerted efforts will be needed at the global, regional, and national levels.
KW - Delphi method
KW - Global health
KW - Non-communicable disease
KW - NAFLD/NASH
KW - Steatotic liver disease
UR - http://www.scopus.com/inward/record.url?scp=85169126126&partnerID=8YFLogxK
U2 - 10.1097/HEP.0000000000000545
DO - 10.1097/HEP.0000000000000545
M3 - Article
C2 - 37540183
SN - 0270-9139
VL - 79
SP - 502
EP - 523
JO - Hepatology
JF - Hepatology
IS - 2
ER -